Progestagens in high-risk pregnancy. What we know today

Q4 Medicine
N.Y. Pedachenko, N.P. Goncharuk, E.F. Chaikivska, T.F. Tatarchuk, T.M. Tutchenko
{"title":"Progestagens in high-risk pregnancy. What we know today","authors":"N.Y. Pedachenko, N.P. Goncharuk, E.F. Chaikivska, T.F. Tatarchuk, T.M. Tutchenko","doi":"10.18370/2309-4117.2023.68.22-28","DOIUrl":null,"url":null,"abstract":"Miscarriage remains an important global problem: 23 million miscarriages are registered annually in the world, i.e. 44 pregnancy losses every minute, and the total risk of miscarriage is 15.3% of all pregnancies. Effective methods of pregnancy preservation (in case of idiopathic miscarriage and threatened miscarriage) include lifestyle modification and progestagen therapy. Progesterone is the main hormone necessary to maintain pregnancy.The effectiveness of progestogens among medical methods that increase the chances of pregnancy preservation has been proven by numerous studies. Effectiveness and safety of various types of progestogens during pregnancy have been studied. As a result, progesterone and dydrogesterone became the only progestogens approved for use in obstetrics – micronized progesterone and dydrogesterone reduce the frequency of miscarriage in women with clinical diagnoses of threatened miscarriage and idiopathic recurrent miscarriage. In addition, the progestogens safety has been carefully studied in modern randomized studies, prospective trials and meta-analyses and the same safety profile of dydrogesterone and micronized progesterone for pregnant women and the fetus has been proven.Studies have shown that oral dydrogesterone has relatively low antagonistic activity at glucocorticoid and mineralocorticoid receptors compared to progesterone and therefore well tolerated. Oral dydrogesterone due to the peculiarities of structure has improved bioavailability compared to progesterone, which allows a woman to avoid the inconvenience and discomfort associated with the intravaginal or intramuscular use of progesterone. In addition, dydrogesterone has a 1.5 times higher affinity for progesterone receptors compared to micronized progesterone and a pronounced anti-inflammatory and immunomodulation effect, which provides certain clinical advantages for patients after recurrent pregnancy losses.Thus, progestogens are indicated for all patients with recurrent pregnancy losses from the moment of receiving a positive pregnancy test, as they reduce the risk of miscarriage. It is important that the use of progestagen drugs during the first and second trimester of pregnancy is not associated with side effects","PeriodicalId":21103,"journal":{"name":"Reproductive Endocrinology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reproductive Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18370/2309-4117.2023.68.22-28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Miscarriage remains an important global problem: 23 million miscarriages are registered annually in the world, i.e. 44 pregnancy losses every minute, and the total risk of miscarriage is 15.3% of all pregnancies. Effective methods of pregnancy preservation (in case of idiopathic miscarriage and threatened miscarriage) include lifestyle modification and progestagen therapy. Progesterone is the main hormone necessary to maintain pregnancy.The effectiveness of progestogens among medical methods that increase the chances of pregnancy preservation has been proven by numerous studies. Effectiveness and safety of various types of progestogens during pregnancy have been studied. As a result, progesterone and dydrogesterone became the only progestogens approved for use in obstetrics – micronized progesterone and dydrogesterone reduce the frequency of miscarriage in women with clinical diagnoses of threatened miscarriage and idiopathic recurrent miscarriage. In addition, the progestogens safety has been carefully studied in modern randomized studies, prospective trials and meta-analyses and the same safety profile of dydrogesterone and micronized progesterone for pregnant women and the fetus has been proven.Studies have shown that oral dydrogesterone has relatively low antagonistic activity at glucocorticoid and mineralocorticoid receptors compared to progesterone and therefore well tolerated. Oral dydrogesterone due to the peculiarities of structure has improved bioavailability compared to progesterone, which allows a woman to avoid the inconvenience and discomfort associated with the intravaginal or intramuscular use of progesterone. In addition, dydrogesterone has a 1.5 times higher affinity for progesterone receptors compared to micronized progesterone and a pronounced anti-inflammatory and immunomodulation effect, which provides certain clinical advantages for patients after recurrent pregnancy losses.Thus, progestogens are indicated for all patients with recurrent pregnancy losses from the moment of receiving a positive pregnancy test, as they reduce the risk of miscarriage. It is important that the use of progestagen drugs during the first and second trimester of pregnancy is not associated with side effects
高危妊娠中的孕激素。我们今天所知道的
流产仍然是一个重要的全球性问题:全世界每年有2300万例流产登记,即每分钟有44例流产,流产的总风险占所有妊娠的15.3%。保存妊娠的有效方法(在特发性流产和先兆流产的情况下)包括生活方式的改变和孕激素治疗。黄体酮是维持妊娠所需的主要激素。孕激素的有效性在医学方法中,增加怀孕的机会保存已被许多研究证明。研究了各种孕激素在妊娠期间的有效性和安全性。因此,孕酮和地孕酮成为唯一被批准用于产科的孕激素——微粉孕酮和地孕酮减少了临床诊断为先兆流产和特发性复发性流产的妇女的流产频率。此外,在现代随机研究、前瞻性试验和荟萃分析中,对孕激素的安全性进行了仔细的研究,并证明了地孕酮和微孕酮对孕妇和胎儿的安全性相同。研究表明,口服地屈孕酮对糖皮质激素和矿皮质激素受体的拮抗活性相对较低,因此耐受性良好。口服地屈孕酮由于其结构的特殊性,与黄体酮相比具有更好的生物利用度,这使得女性避免了阴道内或肌肉内使用黄体酮带来的不便和不适。此外,地孕酮对孕酮受体的亲和力比微粉孕酮高1.5倍,具有明显的抗炎和免疫调节作用,对复发性流产患者具有一定的临床优势。因此,从接受妊娠试验阳性的那一刻起,所有复发性妊娠丢失的患者都应使用孕激素,因为它们可以降低流产的风险。重要的是,在怀孕的前三个月和中期使用孕激素药物与副作用无关
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Reproductive Endocrinology
Reproductive Endocrinology Medicine-Obstetrics and Gynecology
CiteScore
0.50
自引率
0.00%
发文量
13
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信